Early effectiveness of heptavalent conjugate pneumococcal vaccination on invasive pneumococcal disease after the introduction in the Danish Childhood Immunization Programme

Research output: Contribution to journalJournal articlepeer-review

  • Zitta B. Harboe
  • Palle Valentiner-Branth
  • Benfield, Thomas
  • Jens Jørgen Christensen
  • Peter H. S. Andersen
  • Michael Howitz
  • Karen Angeliki Krogfelt
  • Lotte Lambertsen
  • Helle B. Konradsen
We evaluated the effectiveness of the heptavalent pneumococcal conjugate vaccine (PCV7) on invasive pneumococcal disease (IPD) 1 year after PCV7's introduction in the childhood immunization programme through a nationwide cohort study based on laboratory surveillance data. There was a decline in the overall incidence of IPD from 19.4 to 17.1 cases per 100,000 population (incidence rate ratios (IRR) 0.87; 95% confidence interval (CI) [0.81-0.96]), and of meningitis from 1.56 to 1.16 (IRR 0.74; 95% CI [0.57-0.97]) comparing pre-PCV7 (years 2000-2007) and PCV7 (year 2008) periods. In children <2 years, the incidence decreased from 54 to 23 cases per 100,000 (IRR 0.43; 95% CI [0.29-0.62]) and for vaccine-serotypes from 36.7 to 7.7 (IRR 0.20; 95% CI [0.09-0.38]). The incidence of IPD declined approximately 10% (IRR 0.90; 95% CI [0.84-0.97]) in patients aged >or=2 years. The case fatality was 17% in both periods. The administration of PCV7 was followed by a marked decline in the incidence of IPD in both vaccinated and non-vaccinated individuals.
Original languageEnglish
JournalVaccine
Volume28
Issue number14
Pages (from-to)2642–2647
Number of pages6
ISSN0264-410X
DOIs
Publication statusPublished - 2010

Bibliographical note

Keywords: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Child; Child, Preschool; Cohort Studies; Denmark; Female; Humans; Immunization Programs; Incidence; Infant; Infant, Newborn; Male; Middle Aged; Pneumococcal Infections; Pneumococcal Vaccines; Young Adult

ID: 19890884